Abstract
Caffeine is commonly used to prevent or treat apnea in preterm neonates. The present trial was designed to determine the effect of caffeine on reducing the time required for nasal continuous positive airway pressure (NCPAP) in neonates with respiratory distress syndrome (RDS). In a randomized controlled trial, a total of 90 neonates (birth weight between 1250 and 2000 g) who were clinically diagnosed with RDS were subjected to random assignment to one of the two groups of caffeine (n=45) or control (n=45). Infants in the caffeine group received 20 mg/kg caffeine as the initial dose, and then 10 mg/kg daily as the maintenance dose. Infants in the control group did not receive any placebo or similar drugs. The primary outcome was the duration time of respiratory support with NCPAP. The mean (SD) duration of NCPAP differed significantly and was shorter among the infants in the caffeine group than those assigned to the control group (41.53 (43.25) versus 78.48 (114.25) hours, respectively; mean difference: -36.95; 95%CI: -73.14, -0.76; P = 0.04). Apnea of prematurity (AOP) occurred in 2 (4.4%) newborns in the caffeine group and in 9 (20%) of the infants in the control condition [proportion difference: -15.6% (-29.8,-1.8); (P = 0.02)]. The incidence of intraventricular hemorrhage (IVH) was higher in the control group than in the caffeine group after one week (P = 0.03). The incidence of chronic lung disease (CLD), infection, necrotizing enterocolitis (NEC), seizure, vomiting and pneumothorax was similar in the two groups. The results suggest that preventative caffeine can reduce the duration of NCPAP support in neonates with RDS.
Highlights
Methylxanthines have been used to prevent and decrease the rate of apnea in preterm neonates for many years.[1]
In our randomized clinical trial, caffeine could reduce the mean duration required for nasal continuous positive airway pressure (NCPAP) in infants with respiratory distress syndrome (RDS)
Caffeine is widely used as a prophylactic drug for apnea in preterm infants with RDS and birth weights less than 1250 g
Summary
Methylxanthines have been used to prevent and decrease the rate of apnea in preterm neonates for many years.[1]. The positive effects of caffeine are not limited to the prevention and treatment of apnea of prematurity (AOP).[3]. The present trial was designed to determine the effect of caffeine on reducing the time required for nasal continuous positive airway pressure (NCPAP) in neonates with respiratory distress syndrome (RDS). Apnea of prematurity (AOP) occurred in 2 (4.4%) newborns in the caffeine group and in 9 (20%) of the infants in the control condition [proportion difference: -15.6% (-29.8,-1.8); (P = 0.02)]. Conclusion: The results suggest that preventative caffeine can reduce the duration of NCPAP support in neonates with RDS. Effect of prophylactic caffeine on noninvasive respiratory support in preterm neonates weighing 1250–2000 g: a randomized controlled trial. Arch Iran Med. 2022;25(2):98-104. doi: 10.34172/ aim.2022.16
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
